SB2341 EnrolledLRB100 17957 MRW 33141 b

1    AN ACT concerning criminal law.
 
2    Be it enacted by the People of the State of Illinois,
3represented in the General Assembly:
 
4    Section 5. The Illinois Controlled Substances Act is
5amended by changing Sections 102 and 204 as follows:
 
6    (720 ILCS 570/102)  (from Ch. 56 1/2, par. 1102)
7    Sec. 102. Definitions. As used in this Act, unless the
8context otherwise requires:
9    (a) "Addict" means any person who habitually uses any drug,
10chemical, substance or dangerous drug other than alcohol so as
11to endanger the public morals, health, safety or welfare or who
12is so far addicted to the use of a dangerous drug or controlled
13substance other than alcohol as to have lost the power of self
14control with reference to his or her addiction.
15    (b) "Administer" means the direct application of a
16controlled substance, whether by injection, inhalation,
17ingestion, or any other means, to the body of a patient,
18research subject, or animal (as defined by the Humane
19Euthanasia in Animal Shelters Act) by:
20        (1) a practitioner (or, in his or her presence, by his
21    or her authorized agent),
22        (2) the patient or research subject pursuant to an
23    order, or

 

 

SB2341 Enrolled- 2 -LRB100 17957 MRW 33141 b

1        (3) a euthanasia technician as defined by the Humane
2    Euthanasia in Animal Shelters Act.
3    (c) "Agent" means an authorized person who acts on behalf
4of or at the direction of a manufacturer, distributor,
5dispenser, prescriber, or practitioner. It does not include a
6common or contract carrier, public warehouseman or employee of
7the carrier or warehouseman.
8    (c-1) "Anabolic Steroids" means any drug or hormonal
9substance, chemically and pharmacologically related to
10testosterone (other than estrogens, progestins,
11corticosteroids, and dehydroepiandrosterone), and includes:
12    (i) 3[beta],17-dihydroxy-5a-androstane, 
13    (ii) 3[alpha],17[beta]-dihydroxy-5a-androstane, 
14    (iii) 5[alpha]-androstan-3,17-dione, 
15    (iv) 1-androstenediol (3[beta], 
16        17[beta]-dihydroxy-5[alpha]-androst-1-ene), 
17    (v) 1-androstenediol (3[alpha], 
18        17[beta]-dihydroxy-5[alpha]-androst-1-ene), 
19    (vi) 4-androstenediol  
20        (3[beta],17[beta]-dihydroxy-androst-4-ene), 
21    (vii) 5-androstenediol  
22        (3[beta],17[beta]-dihydroxy-androst-5-ene), 
23    (viii) 1-androstenedione  
24        ([5alpha]-androst-1-en-3,17-dione), 
25    (ix) 4-androstenedione  
26        (androst-4-en-3,17-dione), 

 

 

SB2341 Enrolled- 3 -LRB100 17957 MRW 33141 b

1    (x) 5-androstenedione  
2        (androst-5-en-3,17-dione), 
3    (xi) bolasterone (7[alpha],17a-dimethyl-17[beta]- 
4        hydroxyandrost-4-en-3-one), 
5    (xii) boldenone (17[beta]-hydroxyandrost- 
6        1,4,-diene-3-one), 
7    (xiii) boldione (androsta-1,4- 
8        diene-3,17-dione), 
9    (xiv) calusterone (7[beta],17[alpha]-dimethyl-17 
10        [beta]-hydroxyandrost-4-en-3-one), 
11    (xv) clostebol (4-chloro-17[beta]- 
12        hydroxyandrost-4-en-3-one), 
13    (xvi) dehydrochloromethyltestosterone (4-chloro- 
14        17[beta]-hydroxy-17[alpha]-methyl- 
15        androst-1,4-dien-3-one), 
16    (xvii) desoxymethyltestosterone 
17    (17[alpha]-methyl-5[alpha] 
18        -androst-2-en-17[beta]-ol)(a.k.a., madol), 
19    (xviii) [delta]1-dihydrotestosterone (a.k.a.  
20        '1-testosterone') (17[beta]-hydroxy- 
21        5[alpha]-androst-1-en-3-one), 
22    (xix) 4-dihydrotestosterone (17[beta]-hydroxy- 
23        androstan-3-one), 
24    (xx) drostanolone (17[beta]-hydroxy-2[alpha]-methyl- 
25        5[alpha]-androstan-3-one), 
26    (xxi) ethylestrenol (17[alpha]-ethyl-17[beta]- 

 

 

SB2341 Enrolled- 4 -LRB100 17957 MRW 33141 b

1        hydroxyestr-4-ene), 
2    (xxii) fluoxymesterone (9-fluoro-17[alpha]-methyl- 
3        1[beta],17[beta]-dihydroxyandrost-4-en-3-one), 
4    (xxiii) formebolone (2-formyl-17[alpha]-methyl-11[alpha], 
5        17[beta]-dihydroxyandrost-1,4-dien-3-one), 
6    (xxiv) furazabol (17[alpha]-methyl-17[beta]- 
7        hydroxyandrostano[2,3-c]-furazan), 
8    (xxv) 13[beta]-ethyl-17[beta]-hydroxygon-4-en-3-one, ) 
9    (xxvi) 4-hydroxytestosterone (4,17[beta]-dihydroxy- 
10        androst-4-en-3-one), 
11    (xxvii) 4-hydroxy-19-nortestosterone (4,17[beta]- 
12        dihydroxy-estr-4-en-3-one), 
13    (xxviii) mestanolone (17[alpha]-methyl-17[beta]- 
14        hydroxy-5-androstan-3-one), 
15    (xxix) mesterolone (1amethyl-17[beta]-hydroxy- 
16        [5a]-androstan-3-one), 
17    (xxx) methandienone (17[alpha]-methyl-17[beta]- 
18        hydroxyandrost-1,4-dien-3-one), 
19    (xxxi) methandriol (17[alpha]-methyl-3[beta],17[beta]- 
20        dihydroxyandrost-5-ene), 
21    (xxxii) methenolone (1-methyl-17[beta]-hydroxy- 
22        5[alpha]-androst-1-en-3-one), 
23    (xxxiii) 17[alpha]-methyl-3[beta], 17[beta]- 
24        dihydroxy-5a-androstane)
25    (xxxiv) 17[alpha]-methyl-3[alpha],17[beta]-dihydroxy 
26        -5a-androstane)

 

 

SB2341 Enrolled- 5 -LRB100 17957 MRW 33141 b

1    (xxxv) 17[alpha]-methyl-3[beta],17[beta]- 
2        dihydroxyandrost-4-ene), 
3    (xxxvi) 17[alpha]-methyl-4-hydroxynandrolone (17[alpha]- 
4        methyl-4-hydroxy-17[beta]-hydroxyestr-4-en-3-one), 
5    (xxxvii) methyldienolone (17[alpha]-methyl-17[beta]- 
6        hydroxyestra-4,9(10)-dien-3-one), 
7    (xxxviii) methyltrienolone (17[alpha]-methyl-17[beta]- 
8        hydroxyestra-4,9-11-trien-3-one), 
9    (xxxix) methyltestosterone (17[alpha]-methyl-17[beta]- 
10        hydroxyandrost-4-en-3-one), 
11    (xl) mibolerone (7[alpha],17a-dimethyl-17[beta]- 
12        hydroxyestr-4-en-3-one), 
13    (xli) 17[alpha]-methyl-[delta]1-dihydrotestosterone  
14        (17b[beta]-hydroxy-17[alpha]-methyl-5[alpha]- 
15        androst-1-en-3-one)(a.k.a. '17-[alpha]-methyl- 
16        1-testosterone'), 
17    (xlii) nandrolone (17[beta]-hydroxyestr-4-en-3-one), 
18    (xliii) 19-nor-4-androstenediol (3[beta], 17[beta]- 
19        dihydroxyestr-4-ene), 
20    (xliv) 19-nor-4-androstenediol (3[alpha], 17[beta]- 
21        dihydroxyestr-4-ene), 
22    (xlv) 19-nor-5-androstenediol (3[beta], 17[beta]- 
23        dihydroxyestr-5-ene), 
24    (xlvi) 19-nor-5-androstenediol (3[alpha], 17[beta]- 
25        dihydroxyestr-5-ene), 
26    (xlvii) 19-nor-4,9(10)-androstadienedione  

 

 

SB2341 Enrolled- 6 -LRB100 17957 MRW 33141 b

1        (estra-4,9(10)-diene-3,17-dione), 
2    (xlviii) 19-nor-4-androstenedione (estr-4- 
3        en-3,17-dione), 
4    (xlix) 19-nor-5-androstenedione (estr-5- 
5        en-3,17-dione), 
6    (l) norbolethone (13[beta], 17a-diethyl-17[beta]- 
7        hydroxygon-4-en-3-one), 
8    (li) norclostebol (4-chloro-17[beta]- 
9        hydroxyestr-4-en-3-one), 
10    (lii) norethandrolone (17[alpha]-ethyl-17[beta]- 
11        hydroxyestr-4-en-3-one), 
12    (liii) normethandrolone (17[alpha]-methyl-17[beta]- 
13        hydroxyestr-4-en-3-one), 
14    (liv) oxandrolone (17[alpha]-methyl-17[beta]-hydroxy- 
15        2-oxa-5[alpha]-androstan-3-one), 
16    (lv) oxymesterone (17[alpha]-methyl-4,17[beta]- 
17        dihydroxyandrost-4-en-3-one), 
18    (lvi) oxymetholone (17[alpha]-methyl-2-hydroxymethylene- 
19        17[beta]-hydroxy-(5[alpha]-androstan-3-one), 
20    (lvii) stanozolol (17[alpha]-methyl-17[beta]-hydroxy- 
21        (5[alpha]-androst-2-eno[3,2-c]-pyrazole), 
22    (lviii) stenbolone (17[beta]-hydroxy-2-methyl- 
23        (5[alpha]-androst-1-en-3-one), 
24    (lix) testolactone (13-hydroxy-3-oxo-13,17- 
25        secoandrosta-1,4-dien-17-oic 
26        acid lactone), 

 

 

SB2341 Enrolled- 7 -LRB100 17957 MRW 33141 b

1    (lx) testosterone (17[beta]-hydroxyandrost- 
2        4-en-3-one), 
3    (lxi) tetrahydrogestrinone (13[beta], 17[alpha]- 
4        diethyl-17[beta]-hydroxygon- 
5        4,9,11-trien-3-one), 
6    (lxii) trenbolone (17[beta]-hydroxyestr-4,9, 
7        11-trien-3-one). 
8    Any person who is otherwise lawfully in possession of an
9anabolic steroid, or who otherwise lawfully manufactures,
10distributes, dispenses, delivers, or possesses with intent to
11deliver an anabolic steroid, which anabolic steroid is
12expressly intended for and lawfully allowed to be administered
13through implants to livestock or other nonhuman species, and
14which is approved by the Secretary of Health and Human Services
15for such administration, and which the person intends to
16administer or have administered through such implants, shall
17not be considered to be in unauthorized possession or to
18unlawfully manufacture, distribute, dispense, deliver, or
19possess with intent to deliver such anabolic steroid for
20purposes of this Act.
21    (d) "Administration" means the Drug Enforcement
22Administration, United States Department of Justice, or its
23successor agency.
24    (d-5) "Clinical Director, Prescription Monitoring Program"
25means a Department of Human Services administrative employee
26licensed to either prescribe or dispense controlled substances

 

 

SB2341 Enrolled- 8 -LRB100 17957 MRW 33141 b

1who shall run the clinical aspects of the Department of Human
2Services Prescription Monitoring Program and its Prescription
3Information Library.
4    (d-10) "Compounding" means the preparation and mixing of
5components, excluding flavorings, (1) as the result of a
6prescriber's prescription drug order or initiative based on the
7prescriber-patient-pharmacist relationship in the course of
8professional practice or (2) for the purpose of, or incident
9to, research, teaching, or chemical analysis and not for sale
10or dispensing. "Compounding" includes the preparation of drugs
11or devices in anticipation of receiving prescription drug
12orders based on routine, regularly observed dispensing
13patterns. Commercially available products may be compounded
14for dispensing to individual patients only if both of the
15following conditions are met: (i) the commercial product is not
16reasonably available from normal distribution channels in a
17timely manner to meet the patient's needs and (ii) the
18prescribing practitioner has requested that the drug be
19compounded.
20    (e) "Control" means to add a drug or other substance, or
21immediate precursor, to a Schedule whether by transfer from
22another Schedule or otherwise.
23    (f) "Controlled Substance" means (i) a drug, substance,
24immediate precursor, or synthetic drug in the Schedules of
25Article II of this Act or (ii) a drug or other substance, or
26immediate precursor, designated as a controlled substance by

 

 

SB2341 Enrolled- 9 -LRB100 17957 MRW 33141 b

1the Department through administrative rule. The term does not
2include distilled spirits, wine, malt beverages, or tobacco, as
3those terms are defined or used in the Liquor Control Act of
41934 and the Tobacco Products Tax Act of 1995.
5    (f-5) "Controlled substance analog" means a substance:
6        (1) the chemical structure of which is substantially
7    similar to the chemical structure of a controlled substance
8    in Schedule I or II;
9        (2) which has a stimulant, depressant, or
10    hallucinogenic effect on the central nervous system that is
11    substantially similar to or greater than the stimulant,
12    depressant, or hallucinogenic effect on the central
13    nervous system of a controlled substance in Schedule I or
14    II; or
15        (3) with respect to a particular person, which such
16    person represents or intends to have a stimulant,
17    depressant, or hallucinogenic effect on the central
18    nervous system that is substantially similar to or greater
19    than the stimulant, depressant, or hallucinogenic effect
20    on the central nervous system of a controlled substance in
21    Schedule I or II.
22    (g) "Counterfeit substance" means a controlled substance,
23which, or the container or labeling of which, without
24authorization bears the trademark, trade name, or other
25identifying mark, imprint, number or device, or any likeness
26thereof, of a manufacturer, distributor, or dispenser other

 

 

SB2341 Enrolled- 10 -LRB100 17957 MRW 33141 b

1than the person who in fact manufactured, distributed, or
2dispensed the substance.
3    (h) "Deliver" or "delivery" means the actual, constructive
4or attempted transfer of possession of a controlled substance,
5with or without consideration, whether or not there is an
6agency relationship.
7    (i) "Department" means the Illinois Department of Human
8Services (as successor to the Department of Alcoholism and
9Substance Abuse) or its successor agency.
10    (j) (Blank).
11    (k) "Department of Corrections" means the Department of
12Corrections of the State of Illinois or its successor agency.
13    (l) "Department of Financial and Professional Regulation"
14means the Department of Financial and Professional Regulation
15of the State of Illinois or its successor agency.
16    (m) "Depressant" means any drug that (i) causes an overall
17depression of central nervous system functions, (ii) causes
18impaired consciousness and awareness, and (iii) can be
19habit-forming or lead to a substance abuse problem, including
20but not limited to alcohol, cannabis and its active principles
21and their analogs, benzodiazepines and their analogs,
22barbiturates and their analogs, opioids (natural and
23synthetic) and their analogs, and chloral hydrate and similar
24sedative hypnotics.
25    (n) (Blank).
26    (o) "Director" means the Director of the Illinois State

 

 

SB2341 Enrolled- 11 -LRB100 17957 MRW 33141 b

1Police or his or her designated agents.
2    (p) "Dispense" means to deliver a controlled substance to
3an ultimate user or research subject by or pursuant to the
4lawful order of a prescriber, including the prescribing,
5administering, packaging, labeling, or compounding necessary
6to prepare the substance for that delivery.
7    (q) "Dispenser" means a practitioner who dispenses.
8    (r) "Distribute" means to deliver, other than by
9administering or dispensing, a controlled substance.
10    (s) "Distributor" means a person who distributes.
11    (t) "Drug" means (1) substances recognized as drugs in the
12official United States Pharmacopoeia, Official Homeopathic
13Pharmacopoeia of the United States, or official National
14Formulary, or any supplement to any of them; (2) substances
15intended for use in diagnosis, cure, mitigation, treatment, or
16prevention of disease in man or animals; (3) substances (other
17than food) intended to affect the structure of any function of
18the body of man or animals and (4) substances intended for use
19as a component of any article specified in clause (1), (2), or
20(3) of this subsection. It does not include devices or their
21components, parts, or accessories.
22    (t-3) "Electronic health record" or "EHR" means an
23electronic record of health-related information on an
24individual that is created, gathered, managed, and consulted by
25authorized health care clinicians and staff.
26    (t-4) "Emergency medical services personnel" has the

 

 

SB2341 Enrolled- 12 -LRB100 17957 MRW 33141 b

1meaning ascribed to it in the Emergency Medical Services (EMS)
2Systems Act.
3    (t-5) "Euthanasia agency" means an entity certified by the
4Department of Financial and Professional Regulation for the
5purpose of animal euthanasia that holds an animal control
6facility license or animal shelter license under the Animal
7Welfare Act. A euthanasia agency is authorized to purchase,
8store, possess, and utilize Schedule II nonnarcotic and
9Schedule III nonnarcotic drugs for the sole purpose of animal
10euthanasia.
11    (t-10) "Euthanasia drugs" means Schedule II or Schedule III
12substances (nonnarcotic controlled substances) that are used
13by a euthanasia agency for the purpose of animal euthanasia.
14    (u) "Good faith" means the prescribing or dispensing of a
15controlled substance by a practitioner in the regular course of
16professional treatment to or for any person who is under his or
17her treatment for a pathology or condition other than that
18individual's physical or psychological dependence upon or
19addiction to a controlled substance, except as provided herein:
20and application of the term to a pharmacist shall mean the
21dispensing of a controlled substance pursuant to the
22prescriber's order which in the professional judgment of the
23pharmacist is lawful. The pharmacist shall be guided by
24accepted professional standards including, but not limited to
25the following, in making the judgment:
26        (1) lack of consistency of prescriber-patient

 

 

SB2341 Enrolled- 13 -LRB100 17957 MRW 33141 b

1    relationship,
2        (2) frequency of prescriptions for same drug by one
3    prescriber for large numbers of patients,
4        (3) quantities beyond those normally prescribed,
5        (4) unusual dosages (recognizing that there may be
6    clinical circumstances where more or less than the usual
7    dose may be used legitimately),
8        (5) unusual geographic distances between patient,
9    pharmacist and prescriber,
10        (6) consistent prescribing of habit-forming drugs.
11    (u-0.5) "Hallucinogen" means a drug that causes markedly
12altered sensory perception leading to hallucinations of any
13type.
14    (u-1) "Home infusion services" means services provided by a
15pharmacy in compounding solutions for direct administration to
16a patient in a private residence, long-term care facility, or
17hospice setting by means of parenteral, intravenous,
18intramuscular, subcutaneous, or intraspinal infusion.
19    (u-5) "Illinois State Police" means the State Police of the
20State of Illinois, or its successor agency.
21    (v) "Immediate precursor" means a substance:
22        (1) which the Department has found to be and by rule
23    designated as being a principal compound used, or produced
24    primarily for use, in the manufacture of a controlled
25    substance;
26        (2) which is an immediate chemical intermediary used or

 

 

SB2341 Enrolled- 14 -LRB100 17957 MRW 33141 b

1    likely to be used in the manufacture of such controlled
2    substance; and
3        (3) the control of which is necessary to prevent,
4    curtail or limit the manufacture of such controlled
5    substance.
6    (w) "Instructional activities" means the acts of teaching,
7educating or instructing by practitioners using controlled
8substances within educational facilities approved by the State
9Board of Education or its successor agency.
10    (x) "Local authorities" means a duly organized State,
11County or Municipal peace unit or police force.
12    (y) "Look-alike substance" means a substance, other than a
13controlled substance which (1) by overall dosage unit
14appearance, including shape, color, size, markings or lack
15thereof, taste, consistency, or any other identifying physical
16characteristic of the substance, would lead a reasonable person
17to believe that the substance is a controlled substance, or (2)
18is expressly or impliedly represented to be a controlled
19substance or is distributed under circumstances which would
20lead a reasonable person to believe that the substance is a
21controlled substance. For the purpose of determining whether
22the representations made or the circumstances of the
23distribution would lead a reasonable person to believe the
24substance to be a controlled substance under this clause (2) of
25subsection (y), the court or other authority may consider the
26following factors in addition to any other factor that may be

 

 

SB2341 Enrolled- 15 -LRB100 17957 MRW 33141 b

1relevant:
2        (a) statements made by the owner or person in control
3    of the substance concerning its nature, use or effect;
4        (b) statements made to the buyer or recipient that the
5    substance may be resold for profit;
6        (c) whether the substance is packaged in a manner
7    normally used for the illegal distribution of controlled
8    substances;
9        (d) whether the distribution or attempted distribution
10    included an exchange of or demand for money or other
11    property as consideration, and whether the amount of the
12    consideration was substantially greater than the
13    reasonable retail market value of the substance.
14    Clause (1) of this subsection (y) shall not apply to a
15noncontrolled substance in its finished dosage form that was
16initially introduced into commerce prior to the initial
17introduction into commerce of a controlled substance in its
18finished dosage form which it may substantially resemble.
19    Nothing in this subsection (y) prohibits the dispensing or
20distributing of noncontrolled substances by persons authorized
21to dispense and distribute controlled substances under this
22Act, provided that such action would be deemed to be carried
23out in good faith under subsection (u) if the substances
24involved were controlled substances.
25    Nothing in this subsection (y) or in this Act prohibits the
26manufacture, preparation, propagation, compounding,

 

 

SB2341 Enrolled- 16 -LRB100 17957 MRW 33141 b

1processing, packaging, advertising or distribution of a drug or
2drugs by any person registered pursuant to Section 510 of the
3Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360).
4    (y-1) "Mail-order pharmacy" means a pharmacy that is
5located in a state of the United States that delivers,
6dispenses or distributes, through the United States Postal
7Service or other common carrier, to Illinois residents, any
8substance which requires a prescription.
9    (z) "Manufacture" means the production, preparation,
10propagation, compounding, conversion or processing of a
11controlled substance other than methamphetamine, either
12directly or indirectly, by extraction from substances of
13natural origin, or independently by means of chemical
14synthesis, or by a combination of extraction and chemical
15synthesis, and includes any packaging or repackaging of the
16substance or labeling of its container, except that this term
17does not include:
18        (1) by an ultimate user, the preparation or compounding
19    of a controlled substance for his or her own use; or
20        (2) by a practitioner, or his or her authorized agent
21    under his or her supervision, the preparation,
22    compounding, packaging, or labeling of a controlled
23    substance:
24            (a) as an incident to his or her administering or
25        dispensing of a controlled substance in the course of
26        his or her professional practice; or

 

 

SB2341 Enrolled- 17 -LRB100 17957 MRW 33141 b

1            (b) as an incident to lawful research, teaching or
2        chemical analysis and not for sale.
3    (z-1) (Blank).
4    (z-5) "Medication shopping" means the conduct prohibited
5under subsection (a) of Section 314.5 of this Act.
6    (z-10) "Mid-level practitioner" means (i) a physician
7assistant who has been delegated authority to prescribe through
8a written delegation of authority by a physician licensed to
9practice medicine in all of its branches, in accordance with
10Section 7.5 of the Physician Assistant Practice Act of 1987,
11(ii) an advanced practice registered nurse who has been
12delegated authority to prescribe through a written delegation
13of authority by a physician licensed to practice medicine in
14all of its branches or by a podiatric physician, in accordance
15with Section 65-40 of the Nurse Practice Act, (iii) an advanced
16practice registered nurse certified as a nurse practitioner,
17nurse midwife, or clinical nurse specialist who has been
18granted authority to prescribe by a hospital affiliate in
19accordance with Section 65-45 of the Nurse Practice Act, (iv)
20an animal euthanasia agency, or (v) a prescribing psychologist.
21    (aa) "Narcotic drug" means any of the following, whether
22produced directly or indirectly by extraction from substances
23of vegetable origin, or independently by means of chemical
24synthesis, or by a combination of extraction and chemical
25synthesis:
26        (1) opium, opiates, derivatives of opium and opiates,

 

 

SB2341 Enrolled- 18 -LRB100 17957 MRW 33141 b

1    including their isomers, esters, ethers, salts, and salts
2    of isomers, esters, and ethers, whenever the existence of
3    such isomers, esters, ethers, and salts is possible within
4    the specific chemical designation; however the term
5    "narcotic drug" does not include the isoquinoline
6    alkaloids of opium;
7        (2) (blank);
8        (3) opium poppy and poppy straw;
9        (4) coca leaves, except coca leaves and extracts of
10    coca leaves from which substantially all of the cocaine and
11    ecgonine, and their isomers, derivatives and salts, have
12    been removed;
13        (5) cocaine, its salts, optical and geometric isomers,
14    and salts of isomers;
15        (6) ecgonine, its derivatives, their salts, isomers,
16    and salts of isomers;
17        (7) any compound, mixture, or preparation which
18    contains any quantity of any of the substances referred to
19    in subparagraphs (1) through (6).
20    (bb) "Nurse" means a registered nurse licensed under the
21Nurse Practice Act.
22    (cc) (Blank).
23    (dd) "Opiate" means any substance having an addiction
24forming or addiction sustaining liability similar to morphine
25or being capable of conversion into a drug having addiction
26forming or addiction sustaining liability.

 

 

SB2341 Enrolled- 19 -LRB100 17957 MRW 33141 b

1    (ee) "Opium poppy" means the plant of the species Papaver
2somniferum L., except its seeds.
3    (ee-5) "Oral dosage" means a tablet, capsule, elixir, or
4solution or other liquid form of medication intended for
5administration by mouth, but the term does not include a form
6of medication intended for buccal, sublingual, or transmucosal
7administration.
8    (ff) "Parole and Pardon Board" means the Parole and Pardon
9Board of the State of Illinois or its successor agency.
10    (gg) "Person" means any individual, corporation,
11mail-order pharmacy, government or governmental subdivision or
12agency, business trust, estate, trust, partnership or
13association, or any other entity.
14    (hh) "Pharmacist" means any person who holds a license or
15certificate of registration as a registered pharmacist, a local
16registered pharmacist or a registered assistant pharmacist
17under the Pharmacy Practice Act.
18    (ii) "Pharmacy" means any store, ship or other place in
19which pharmacy is authorized to be practiced under the Pharmacy
20Practice Act.
21    (ii-5) "Pharmacy shopping" means the conduct prohibited
22under subsection (b) of Section 314.5 of this Act.
23    (ii-10) "Physician" (except when the context otherwise
24requires) means a person licensed to practice medicine in all
25of its branches.
26    (jj) "Poppy straw" means all parts, except the seeds, of

 

 

SB2341 Enrolled- 20 -LRB100 17957 MRW 33141 b

1the opium poppy, after mowing.
2    (kk) "Practitioner" means a physician licensed to practice
3medicine in all its branches, dentist, optometrist, podiatric
4physician, veterinarian, scientific investigator, pharmacist,
5physician assistant, advanced practice registered nurse,
6licensed practical nurse, registered nurse, emergency medical
7services personnel, hospital, laboratory, or pharmacy, or
8other person licensed, registered, or otherwise lawfully
9permitted by the United States or this State to distribute,
10dispense, conduct research with respect to, administer or use
11in teaching or chemical analysis, a controlled substance in the
12course of professional practice or research.
13    (ll) "Pre-printed prescription" means a written
14prescription upon which the designated drug has been indicated
15prior to the time of issuance; the term does not mean a written
16prescription that is individually generated by machine or
17computer in the prescriber's office.
18    (mm) "Prescriber" means a physician licensed to practice
19medicine in all its branches, dentist, optometrist,
20prescribing psychologist licensed under Section 4.2 of the
21Clinical Psychologist Licensing Act with prescriptive
22authority delegated under Section 4.3 of the Clinical
23Psychologist Licensing Act, podiatric physician, or
24veterinarian who issues a prescription, a physician assistant
25who issues a prescription for a controlled substance in
26accordance with Section 303.05, a written delegation, and a

 

 

SB2341 Enrolled- 21 -LRB100 17957 MRW 33141 b

1written collaborative agreement required under Section 7.5 of
2the Physician Assistant Practice Act of 1987, an advanced
3practice registered nurse with prescriptive authority
4delegated under Section 65-40 of the Nurse Practice Act and in
5accordance with Section 303.05, a written delegation, and a
6written collaborative agreement under Section 65-35 of the
7Nurse Practice Act, an advanced practice registered nurse
8certified as a nurse practitioner, nurse midwife, or clinical
9nurse specialist who has been granted authority to prescribe by
10a hospital affiliate in accordance with Section 65-45 of the
11Nurse Practice Act and in accordance with Section 303.05, or an
12advanced practice registered nurse certified as a nurse
13practitioner, nurse midwife, or clinical nurse specialist who
14has full practice authority pursuant to Section 65-43 of the
15Nurse Practice Act.
16    (nn) "Prescription" means a written, facsimile, or oral
17order, or an electronic order that complies with applicable
18federal requirements, of a physician licensed to practice
19medicine in all its branches, dentist, podiatric physician or
20veterinarian for any controlled substance, of an optometrist in
21accordance with Section 15.1 of the Illinois Optometric
22Practice Act of 1987, of a prescribing psychologist licensed
23under Section 4.2 of the Clinical Psychologist Licensing Act
24with prescriptive authority delegated under Section 4.3 of the
25Clinical Psychologist Licensing Act, of a physician assistant
26for a controlled substance in accordance with Section 303.05, a

 

 

SB2341 Enrolled- 22 -LRB100 17957 MRW 33141 b

1written delegation, and a written collaborative agreement
2required under Section 7.5 of the Physician Assistant Practice
3Act of 1987, of an advanced practice registered nurse with
4prescriptive authority delegated under Section 65-40 of the
5Nurse Practice Act who issues a prescription for a controlled
6substance in accordance with Section 303.05, a written
7delegation, and a written collaborative agreement under
8Section 65-35 of the Nurse Practice Act, of an advanced
9practice registered nurse certified as a nurse practitioner,
10nurse midwife, or clinical nurse specialist who has been
11granted authority to prescribe by a hospital affiliate in
12accordance with Section 65-45 of the Nurse Practice Act and in
13accordance with Section 303.05 when required by law, or of an
14advanced practice registered nurse certified as a nurse
15practitioner, nurse midwife, or clinical nurse specialist who
16has full practice authority pursuant to Section 65-43 of the
17Nurse Practice Act.
18    (nn-5) "Prescription Information Library" (PIL) means an
19electronic library that contains reported controlled substance
20data.
21    (nn-10) "Prescription Monitoring Program" (PMP) means the
22entity that collects, tracks, and stores reported data on
23controlled substances and select drugs pursuant to Section 316.
24    (oo) "Production" or "produce" means manufacture,
25planting, cultivating, growing, or harvesting of a controlled
26substance other than methamphetamine.

 

 

SB2341 Enrolled- 23 -LRB100 17957 MRW 33141 b

1    (pp) "Registrant" means every person who is required to
2register under Section 302 of this Act.
3    (qq) "Registry number" means the number assigned to each
4person authorized to handle controlled substances under the
5laws of the United States and of this State.
6    (qq-5) "Secretary" means, as the context requires, either
7the Secretary of the Department or the Secretary of the
8Department of Financial and Professional Regulation, and the
9Secretary's designated agents.
10    (rr) "State" includes the State of Illinois and any state,
11district, commonwealth, territory, insular possession thereof,
12and any area subject to the legal authority of the United
13States of America.
14    (rr-5) "Stimulant" means any drug that (i) causes an
15overall excitation of central nervous system functions, (ii)
16causes impaired consciousness and awareness, and (iii) can be
17habit-forming or lead to a substance abuse problem, including
18but not limited to amphetamines and their analogs,
19methylphenidate and its analogs, cocaine, and phencyclidine
20and its analogs.
21    (rr-10) "Synthetic drug" includes, but is not limited to,
22any synthetic cannabinoids or piperazines or any synthetic
23cathinones as provided for in Schedule I.
24    (ss) "Ultimate user" means a person who lawfully possesses
25a controlled substance for his or her own use or for the use of
26a member of his or her household or for administering to an

 

 

SB2341 Enrolled- 24 -LRB100 17957 MRW 33141 b

1animal owned by him or her or by a member of his or her
2household.
3(Source: P.A. 99-78, eff. 7-20-15; 99-173, eff. 7-29-15;
499-371, eff. 1-1-16; 99-480, eff. 9-9-15; 99-642, eff. 7-28-16;
5100-280, eff. 1-1-18; 100-453, eff. 8-25-17; 100-513, eff.
61-1-18; revised 10-6-17.)
 
7    (720 ILCS 570/204)  (from Ch. 56 1/2, par. 1204)
8    Sec. 204. (a) The controlled substances listed in this
9Section are included in Schedule I.
10    (b) Unless specifically excepted or unless listed in
11another schedule, any of the following opiates, including their
12isomers, esters, ethers, salts, and salts of isomers, esters,
13and ethers, whenever the existence of such isomers, esters,
14ethers and salts is possible within the specific chemical
15designation:
16        (1) Acetylmethadol;
17        (1.1) Acetyl-alpha-methylfentanyl
18    (N-[1-(1-methyl-2-phenethyl)-
19    4-piperidinyl]-N-phenylacetamide);
20        (2) Allylprodine;
21        (3) Alphacetylmethadol, except
22    levo-alphacetylmethadol (also known as levo-alpha-
23    acetylmethadol, levomethadyl acetate, or LAAM);
24        (4) Alphameprodine;
25        (5) Alphamethadol;

 

 

SB2341 Enrolled- 25 -LRB100 17957 MRW 33141 b

1        (6) Alpha-methylfentanyl
2    (N-(1-alpha-methyl-beta-phenyl) ethyl-4-piperidyl)
3    propionanilide;  1-(1-methyl-2-phenylethyl)-4-(N-
4    propanilido) piperidine;
5        (6.1) Alpha-methylthiofentanyl
6    (N-[1-methyl-2-(2-thienyl)ethyl-
7    4-piperidinyl]-N-phenylpropanamide);
8        (7) 1-methyl-4-phenyl-4-propionoxypiperidine (MPPP);
9        (7.1) PEPAP
10    (1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine);
11        (8) Benzethidine;
12        (9) Betacetylmethadol;
13        (9.1) Beta-hydroxyfentanyl
14    (N-[1-(2-hydroxy-2-phenethyl)-
15    4-piperidinyl]-N-phenylpropanamide);
16        (10) Betameprodine;
17        (11) Betamethadol;
18        (12) Betaprodine;
19        (13) Clonitazene;
20        (14) Dextromoramide;
21        (15) Diampromide;
22        (16) Diethylthiambutene;
23        (17) Difenoxin;
24        (18) Dimenoxadol;
25        (19) Dimepheptanol;
26        (20) Dimethylthiambutene;

 

 

SB2341 Enrolled- 26 -LRB100 17957 MRW 33141 b

1        (21) Dioxaphetylbutyrate;
2        (22) Dipipanone;
3        (23) Ethylmethylthiambutene;
4        (24) Etonitazene;
5        (25) Etoxeridine;
6        (26) Furethidine;
7        (27) Hydroxpethidine;
8        (28) Ketobemidone;
9        (29) Levomoramide;
10        (30) Levophenacylmorphan;
11        (31) 3-Methylfentanyl
12    (N-[3-methyl-1-(2-phenylethyl)-
13    4-piperidyl]-N-phenylpropanamide);
14        (31.1) 3-Methylthiofentanyl
15    (N-[(3-methyl-1-(2-thienyl)ethyl-
16    4-piperidinyl]-N-phenylpropanamide);
17        (32) Morpheridine;
18        (33) Noracymethadol;
19        (34) Norlevorphanol;
20        (35) Normethadone;
21        (36) Norpipanone;
22        (36.1) Para-fluorofentanyl
23    (N-(4-fluorophenyl)-N-[1-(2-phenethyl)-
24    4-piperidinyl]propanamide);
25        (37) Phenadoxone;
26        (38) Phenampromide;

 

 

SB2341 Enrolled- 27 -LRB100 17957 MRW 33141 b

1        (39) Phenomorphan;
2        (40) Phenoperidine;
3        (41) Piritramide;
4        (42) Proheptazine;
5        (43) Properidine;
6        (44) Propiram;
7        (45) Racemoramide;
8        (45.1) Thiofentanyl
9    (N-phenyl-N-[1-(2-thienyl)ethyl-
10    4-piperidinyl]-propanamide);
11        (46) Tilidine;
12        (47) Trimeperidine;
13        (48) Beta-hydroxy-3-methylfentanyl (other name:
14    N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]-
15    N-phenylpropanamide);
16        (49) Furanyl fentanyl (FU-F);
17        (50) Butyryl fentanyl;
18        (51) Valeryl fentanyl;
19        (52) Acetyl fentanyl;
20        (53) Beta-hydroxy-thiofentanyl;
21        (54) 3,4-dichloro-N-[2-
22    (dimethylamino)cyclohexyl]-N-
23    methylbenzamide (U-47700); 
24        (55) 4-chloro-N-[1-[2-
25    (4-nitrophenyl)ethyl]-2-piperidinylidene]-
26    benzenesulfonamide (W-18); 

 

 

SB2341 Enrolled- 28 -LRB100 17957 MRW 33141 b

1        (56) 4-chloro-N-[1-(2-phenylethyl)
2    -2-piperidinylidene]-benzenesulfonamide (W-15); 
3        (57) acrylfentanyl (acryloylfentanyl). 
4    (c) Unless specifically excepted or unless listed in
5another schedule, any of the following opium derivatives, its
6salts, isomers and salts of isomers, whenever the existence of
7such salts, isomers and salts of isomers is possible within the
8specific chemical designation:
9        (1) Acetorphine;
10        (2) Acetyldihydrocodeine;
11        (3) Benzylmorphine;
12        (4) Codeine methylbromide;
13        (5) Codeine-N-Oxide;
14        (6) Cyprenorphine;
15        (7) Desomorphine;
16        (8) Diacetyldihydromorphine (Dihydroheroin);
17        (9) Dihydromorphine;
18        (10) Drotebanol;
19        (11) Etorphine (except hydrochloride salt);
20        (12) Heroin;
21        (13) Hydromorphinol;
22        (14) Methyldesorphine;
23        (15) Methyldihydromorphine;
24        (16) Morphine methylbromide;
25        (17) Morphine methylsulfonate;
26        (18) Morphine-N-Oxide;

 

 

SB2341 Enrolled- 29 -LRB100 17957 MRW 33141 b

1        (19) Myrophine;
2        (20) Nicocodeine;
3        (21) Nicomorphine;
4        (22) Normorphine;
5        (23) Pholcodine;
6        (24) Thebacon.
7    (d) Unless specifically excepted or unless listed in
8another schedule, any material, compound, mixture, or
9preparation which contains any quantity of the following
10hallucinogenic substances, or which contains any of its salts,
11isomers and salts of isomers, whenever the existence of such
12salts, isomers, and salts of isomers is possible within the
13specific chemical designation (for the purposes of this
14paragraph only, the term "isomer" includes the optical,
15position and geometric isomers):
16        (1) 3,4-methylenedioxyamphetamine
17    (alpha-methyl,3,4-methylenedioxyphenethylamine,
18    methylenedioxyamphetamine, MDA);
19        (1.1) Alpha-ethyltryptamine
20    (some trade or other names: etryptamine;
21    MONASE; alpha-ethyl-1H-indole-3-ethanamine;
22    3-(2-aminobutyl)indole; a-ET; and AET);
23        (2) 3,4-methylenedioxymethamphetamine (MDMA);
24        (2.1) 3,4-methylenedioxy-N-ethylamphetamine
25    (also known as: N-ethyl-alpha-methyl-
26    3,4(methylenedioxy) Phenethylamine, N-ethyl MDA, MDE,

 

 

SB2341 Enrolled- 30 -LRB100 17957 MRW 33141 b

1    and MDEA);
2        (2.2) N-Benzylpiperazine (BZP);
3        (2.2-1) Trifluoromethylphenylpiperazine (TFMPP);
4        (3) 3-methoxy-4,5-methylenedioxyamphetamine, (MMDA);
5        (4) 3,4,5-trimethoxyamphetamine (TMA);
6        (5) (Blank);
7        (6) Diethyltryptamine (DET);
8        (7) Dimethyltryptamine (DMT);
9        (7.1) 5-Methoxy-diallyltryptamine;
10        (8) 4-methyl-2,5-dimethoxyamphetamine (DOM, STP);
11        (9) Ibogaine  (some trade and other names:
12    7-ethyl-6,6,beta,7,8,9,10,12,13-octahydro-2-methoxy-
13    6,9-methano-5H-pyrido [1',2':1,2] azepino [5,4-b]
14    indole; Tabernanthe iboga);
15        (10) Lysergic acid diethylamide;
16        (10.1) Salvinorin A;
17        (10.5) Salvia divinorum (meaning all parts of the plant
18    presently classified botanically as Salvia divinorum,
19    whether growing or not, the seeds thereof, any extract from
20    any part of that plant, and every compound, manufacture,
21    salts, isomers, and salts of isomers whenever the existence
22    of such salts, isomers, and salts of isomers is possible
23    within the specific chemical designation, derivative,
24    mixture, or preparation of that plant, its seeds or
25    extracts);
26        (11) 3,4,5-trimethoxyphenethylamine (Mescaline);

 

 

SB2341 Enrolled- 31 -LRB100 17957 MRW 33141 b

1        (12) Peyote (meaning all parts of the plant presently
2    classified botanically as Lophophora williamsii Lemaire,
3    whether growing or not, the seeds thereof, any extract from
4    any part of that plant, and every compound, manufacture,
5    salts, derivative, mixture, or preparation of that plant,
6    its seeds or extracts);
7        (13) N-ethyl-3-piperidyl benzilate (JB 318);
8        (14) N-methyl-3-piperidyl benzilate;
9        (14.1) N-hydroxy-3,4-methylenedioxyamphetamine
10    (also known as N-hydroxy-alpha-methyl-
11    3,4(methylenedioxy)phenethylamine and N-hydroxy MDA);
12        (15) Parahexyl; some trade or other names:
13    3-hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-
14    dibenzo (b,d) pyran; Synhexyl;
15        (16) Psilocybin;
16        (17) Psilocyn;
17        (18) Alpha-methyltryptamine (AMT);
18        (19) 2,5-dimethoxyamphetamine
19    (2,5-dimethoxy-alpha-methylphenethylamine; 2,5-DMA);
20        (20) 4-bromo-2,5-dimethoxyamphetamine
21    (4-bromo-2,5-dimethoxy-alpha-methylphenethylamine;
22    4-bromo-2,5-DMA);
23        (20.1) 4-Bromo-2,5 dimethoxyphenethylamine.
24    Some trade or other names: 2-(4-bromo-
25    2,5-dimethoxyphenyl)-1-aminoethane;
26    alpha-desmethyl DOB, 2CB, Nexus;

 

 

SB2341 Enrolled- 32 -LRB100 17957 MRW 33141 b

1        (21) 4-methoxyamphetamine
2    (4-methoxy-alpha-methylphenethylamine;
3    paramethoxyamphetamine; PMA);
4        (22) (Blank);
5        (23) Ethylamine analog of phencyclidine.
6    Some trade or other names:
7    N-ethyl-1-phenylcyclohexylamine,
8    (1-phenylcyclohexyl) ethylamine,
9    N-(1-phenylcyclohexyl) ethylamine, cyclohexamine, PCE;
10        (24) Pyrrolidine analog of phencyclidine. Some trade
11    or other names: 1-(1-phenylcyclohexyl) pyrrolidine, PCPy,
12    PHP;
13        (25) 5-methoxy-3,4-methylenedioxy-amphetamine;
14        (26) 2,5-dimethoxy-4-ethylamphetamine
15    (another name: DOET);
16        (27) 1-[1-(2-thienyl)cyclohexyl] pyrrolidine
17    (another name: TCPy);
18        (28) (Blank);
19        (29) Thiophene analog of phencyclidine (some trade
20    or other names: 1-[1-(2-thienyl)-cyclohexyl]-piperidine;
21    2-thienyl analog of phencyclidine; TPCP; TCP);
22        (29.1) Benzothiophene analog of phencyclidine. Some
23    trade or other names: BTCP or benocyclidine;
24        (29.2) 3-Methoxyphencyclidine (3-MeO-PCP);
25        (30) Bufotenine (some trade or other names:
26    3-(Beta-Dimethylaminoethyl)-5-hydroxyindole;

 

 

SB2341 Enrolled- 33 -LRB100 17957 MRW 33141 b

1    3-(2-dimethylaminoethyl)-5-indolol;
2    5-hydroxy-N,N-dimethyltryptamine;
3    N,N-dimethylserotonin; mappine);
4        (31) (Blank);  
5        (32) (Blank);  
6        (33) (Blank);  
7        (34) (Blank); 
8        (34.5) (Blank);  
9        (35) (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-
10    (2-methyloctan-2-yl)-6a,7, 
11    10,10a-tetrahydrobenzo[c]chromen-1-ol
12    Some trade or other names: HU-210; 
13        (35.5)  (6aS,10aS)-9-(hydroxymethyl)-6,6- 
14    dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a- 
15    tetrahydrobenzo[c]chromen-1-ol, its isomers,  
16    salts, and salts of isomers; Some trade or other  
17    names: HU-210, Dexanabinol; 
18        (36) Dexanabinol, (6aS,10aS)-9-(hydroxymethyl)-
19    6,6-dimethyl-3-(2-methyloctan-2-yl)- 
20    6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol
21    Some trade or other names: HU-211;
22        (37) (Blank);
23        (38) (Blank);
24        (39) (Blank);
25        (40) (Blank);
26        (41) (Blank);

 

 

SB2341 Enrolled- 34 -LRB100 17957 MRW 33141 b

1        (42) Any compound structurally derived from
2    3-(1-naphthoyl)indole or 1H-indol-3-yl-(1-naphthyl)methane
3    by substitution at the nitrogen atom of the indole ring by
4    alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
5    cycloalkylethyl, aryl halide, alkyl aryl halide,
6    1-(N-methyl-2-piperidinyl)methyl, or
7    2-(4-morpholinyl)ethyl whether or not further substituted
8    in the indole ring to any extent, whether or not
9    substituted in the naphthyl ring to any extent. Examples of
10    this structural class include, but are not limited to,
11    JWH-018, AM-2201, JWH-175, JWH-184, and JWH-185;
12        (43) Any compound structurally derived from
13    3-(1-naphthoyl)pyrrole by substitution at the nitrogen
14    atom of the pyrrole ring by alkyl, haloalkyl, alkenyl,
15    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
16    halide, 1-(N-methyl-2-piperidinyl)methyl, or
17    2-(4-morpholinyl)ethyl, whether or not further substituted
18    in the pyrrole ring to any extent, whether or not
19    substituted in the naphthyl ring to any extent. Examples of
20    this structural class include, but are not limited to,
21    JWH-030, JWH-145, JWH-146, JWH-307, and JWH-368;
22        (44) Any compound structurally derived from
23    1-(1-naphthylmethyl)indene by substitution at the
24    3-position of the indene ring by alkyl, haloalkyl, alkenyl,
25    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
26    halide, 1-(N-methyl-2-piperidinyl)methyl, or

 

 

SB2341 Enrolled- 35 -LRB100 17957 MRW 33141 b

1    2-(4-morpholinyl)ethyl whether or not further substituted
2    in the indene ring to any extent, whether or not
3    substituted in the naphthyl ring to any extent. Examples of
4    this structural class include, but are not limited to,
5    JWH-176;
6        (45) Any compound structurally derived from
7    3-phenylacetylindole by substitution at the nitrogen atom
8    of the indole ring with alkyl, haloalkyl, alkenyl,
9    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
10    halide, 1-(N-methyl-2-piperidinyl)methyl, or
11    2-(4-morpholinyl)ethyl, whether or not further substituted
12    in the indole ring to any extent, whether or not
13    substituted in the phenyl ring to any extent. Examples of
14    this structural class include, but are not limited to,
15    JWH-167, JWH-250, JWH-251, and RCS-8;
16        (46) Any compound structurally derived from
17    2-(3-hydroxycyclohexyl)phenol by substitution at the
18    5-position of the phenolic ring by alkyl, haloalkyl,
19    alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
20    alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
21    2-(4-morpholinyl)ethyl, whether or not substituted in the
22    cyclohexyl ring to any extent. Examples of this structural
23    class include, but are not limited to, CP 47, 497 and its
24    C8 homologue (cannabicyclohexanol);
25        (46.1) Any compound structurally derived from
26    3-(benzoyl) indole with substitution at the nitrogen atom

 

 

SB2341 Enrolled- 36 -LRB100 17957 MRW 33141 b

1    of the indole ring by an alkyl, haloalkyl, alkenyl,
2    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
3    halide, 1-(N-methyl-2-piperidinyl)methyl, or
4    2-(4-morpholinyl)ethyl group whether or not further
5    substituted in the indole ring to any extent and whether or
6    not substituted in the phenyl ring to any extent. Examples
7    of this structural class include, but are not limited to,
8    AM-630, AM-2233, AM-694, Pravadoline (WIN 48,098), and
9    RCS-4;
10        (47) (Blank);
11        (48) (Blank);
12        (49) (Blank);
13        (50) (Blank);
14        (51) (Blank);
15        (52) (Blank);
16        (53) 2,5-Dimethoxy-4-(n)-propylthio-phenethylamine.
17    Some trade or other names: 2C-T-7;
18        (53.1) 4-ethyl-2,5-dimethoxyphenethylamine. Some trade
19    or other names: 2C-E;
20        (53.2) 2,5-dimethoxy-4-methylphenethylamine. Some
21    trade or other names: 2C-D;
22        (53.3) 4-chloro-2,5-dimethoxyphenethylamine. Some
23    trade or other names: 2C-C;
24        (53.4) 4-iodo-2,5-dimethoxyphenethylamine. Some trade
25    or other names: 2C-I;
26        (53.5) 4-ethylthio-2,5-dimethoxyphenethylamine. Some

 

 

SB2341 Enrolled- 37 -LRB100 17957 MRW 33141 b

1    trade or other names: 2C-T-2;
2        (53.6) 2,5-dimethoxy-4-isopropylthio-phenethylamine.
3    Some trade or other names: 2C-T-4;
4        (53.7) 2,5-dimethoxyphenethylamine. Some trade or
5    other names: 2C-H;
6        (53.8) 2,5-dimethoxy-4-nitrophenethylamine. Some trade
7    or other names: 2C-N;
8        (53.9) 2,5-dimethoxy-4-(n)-propylphenethylamine. Some
9    trade or other names: 2C-P;
10        (53.10) 2,5-dimethoxy-3,4-dimethylphenethylamine. Some
11    trade or other names: 2C-G;
12        (53.11) The N-(2-methoxybenzyl) derivative of any 2C
13    phenethylamine referred to in subparagraphs (20.1), (53),
14    (53.1), (53.2), (53.3), (53.4), (53.5), (53.6), (53.7),
15    (53.8), (53.9), and (53.10) including, but not limited to,
16    25I-NBOMe and 25C-NBOMe;
17        (54) 5-Methoxy-N,N-diisopropyltryptamine;
18        (55) (Blank);
19        (56) (Blank);
20        (57) (Blank);
21        (58) (Blank);
22        (59) 3-cyclopropoylindole with substitution at the
23    nitrogen atom of the indole ring by alkyl, haloalkyl,
24    alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
25    alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
26    2-(4-morpholinyl)ethyl, whether or not further substituted

 

 

SB2341 Enrolled- 38 -LRB100 17957 MRW 33141 b

1    on the indole ring to any extent, whether or not
2    substituted on the cyclopropyl ring to any extent:
3    including, but not limited to, XLR11, UR144, FUB-144;
4        (60) 3-adamantoylindole with substitution at the
5    nitrogen atom of the indole ring by alkyl, haloalkyl,
6    alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
7    alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
8    2-(4-morpholinyl)ethyl, whether or not further substituted
9    on the indole ring to any extent, whether or not
10    substituted on the adamantyl ring to any extent: including,
11    but not limited to, AB-001;
12        (61) N-(adamantyl)-indole-3-carboxamide with
13    substitution at the nitrogen atom of the indole ring by
14    alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
15    cycloalkylethyl, aryl halide, alkyl aryl halide,
16    1-(N-methyl-2-piperidinyl)methyl, or
17    2-(4-morpholinyl)ethyl, whether or not further substituted
18    on the indole ring to any extent, whether or not
19    substituted on the adamantyl ring to any extent: including,
20    but not limited to, APICA/2NE-1, STS-135;
21        (62) N-(adamantyl)-indazole-3-carboxamide with
22    substitution at a nitrogen atom of the indazole ring by
23    alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
24    cycloalkylethyl, aryl halide, alkyl aryl halide,
25    1-(N-methyl-2-piperidinyl)methyl, or
26    2-(4-morpholinyl)ethyl, whether or not further substituted

 

 

SB2341 Enrolled- 39 -LRB100 17957 MRW 33141 b

1    on the indazole ring to any extent, whether or not
2    substituted on the adamantyl ring to any extent: including,
3    but not limited to, AKB48, 5F-AKB48;
4        (63) 1H-indole-3-carboxylic acid 8-quinolinyl ester
5    with substitution at the nitrogen atom of the indole ring
6    by alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
7    cycloalkylethyl, aryl halide, alkyl aryl halide,
8    1-(N-methyl-2-piperidinyl)methyl, or
9    2-(4-morpholinyl)ethyl, whether or not further substituted
10    on the indole ring to any extent, whether or not
11    substituted on the quinoline ring to any extent: including,
12    but not limited to, PB22, 5F-PB22, FUB-PB-22;
13        (64) 3-(1-naphthoyl)indazole with substitution at the
14    nitrogen atom of the indazole ring by alkyl, haloalkyl,
15    alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
16    alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
17    2-(4-morpholinyl)ethyl, whether or not further substituted
18    on the indazole ring to any extent, whether or not
19    substituted on the naphthyl ring to any extent: including,
20    but not limited to, THJ-018, THJ-2201;
21        (65) 2-(1-naphthoyl)benzimidazole with substitution at
22    the nitrogen atom of the benzimidazole ring by alkyl,
23    haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
24    aryl halide, alkyl aryl halide,
25    1-(N-methyl-2-piperidinyl)methyl, or
26    2-(4-morpholinyl)ethyl, whether or not further substituted

 

 

SB2341 Enrolled- 40 -LRB100 17957 MRW 33141 b

1    on the benzimidazole ring to any extent, whether or not
2    substituted on the naphthyl ring to any extent: including,
3    but not limited to, FUBIMINA;
4        (66) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1H-indazole-
5    3-carboxamide with substitution on the nitrogen atom of the
6    indazole ring by alkyl, haloalkyl, alkenyl,
7    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
8    halide, 1-(N-methyl-2-piperidinyl)methyl, or
9    2-(4-morpholinyl)ethyl, whether or not further substituted
10    on the indazole ring to any extent: including, but not
11    limited to, AB-PINACA, AB-FUBINACA, AB-CHMINACA;
12        (67) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1H-
13    indazole-3-carboxamide with substitution on the nitrogen
14    atom of the indazole ring by alkyl, haloalkyl, alkenyl,
15    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
16    halide, 1-(N-methyl-2-piperidinyl)methyl, or
17    2-(4-morpholinyl)ethyl, whether or not further substituted
18    on the indazole ring to any extent: including, but not
19    limited to, ADB-PINACA, ADB-FUBINACA;
20        (68) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1H-
21    indole-3-carboxamide with substitution on the nitrogen
22    atom of the indole ring by alkyl, haloalkyl, alkenyl,
23    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
24    halide, 1-(N-methyl-2-piperidinyl)methyl, or
25    2-(4-morpholinyl)ethyl, whether or not further substituted
26    on the indole ring to any extent: including, but not

 

 

SB2341 Enrolled- 41 -LRB100 17957 MRW 33141 b

1    limited to, ADBICA, 5F-ADBICA;
2        (69) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1H-indole-
3    3-carboxamide with substitution on the nitrogen atom of the
4    indole ring by alkyl, haloalkyl, alkenyl,
5    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
6    halide, 1-(N-methyl-2-piperidinyl)methyl, or
7    2-(4-morpholinyl)ethyl, whether or not further substituted
8    on the indole ring to any extent: including, but not
9    limited to, ABICA, 5F-ABICA;
10        (70) Methyl 2-(1H-indazole-3-carboxamido)-3-
11    methylbutanoate with substitution on the nitrogen atom of
12    the indazole ring by alkyl, haloalkyl, alkenyl,
13    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
14    halide, 1-(N-methyl-2-piperidinyl)methyl, or
15    2-(4-morpholinyl)ethyl, whether or not further substituted
16    on the indazole ring to any extent: including, but not
17    limited to, AMB, 5F-AMB; .
18        (71) Methyl 2-(1H-indazole-3-carboxamido)-3,3-
19    dimethylbutanoate with substitution on the nitrogen atom
20    of the indazole ring by alkyl, haloalkyl, alkenyl,
21    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
22    halide, 1-(N-methyl-2-piperidinyl)methyl, or
23    2-(4-morpholinyl)ethyl, whether or not further substituted
24    on the indazole ring to any extent: including, but not
25    limited to, 5-fluoro-MDMB-PINACA, MDMB-FUBINACA;
26        (72) Methyl 2-(1H-indole-3-carboxamido)-3-

 

 

SB2341 Enrolled- 42 -LRB100 17957 MRW 33141 b

1    methylbutanoate with substitution on the nitrogen atom of
2    the indole ring by alkyl, haloalkyl, alkenyl,
3    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
4    halide, 1-(N-methyl-2-piperidinyl)methyl, or
5    2-(4-morpholinyl)ethyl, whether or not further substituted
6    on the indazole ring to any extent: including, but not
7    limited to, MMB018, MMB2201, and AMB-CHMICA;
8        (73) Methyl 2-(1H-indole-3-carboxamido)-3,3-
9    dimethylbutanoate with substitution on the nitrogen atom
10    of the indole ring by alkyl, haloalkyl, alkenyl,
11    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
12    halide, 1-(N-methyl-2-piperidinyl)methyl, or
13    2-(4-morpholinyl)ethyl, whether or not further substituted
14    on the indazole ring to any extent: including, but not
15    limited to, MDMB-CHMICA;
16        (74) N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1H-
17    indazole-3-carboxamide with substitution on the nitrogen
18    atom of the indazole ring by alkyl, haloalkyl, alkenyl,
19    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
20    halide, 1-(N-methyl-2-piperidinyl)methyl, or
21    2-(4-morpholinyl)ethyl, whether or not further substituted
22    on the indazole ring to any     extent: including, but not
23    limited to, APP-CHMINACA, 5-fluoro-APP-PINACA;
24        (75) N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1H-indole-
25    3-carboxamide with substitution on the nitrogen atom of the
26    indole ring by alkyl, haloalkyl, alkenyl,

 

 

SB2341 Enrolled- 43 -LRB100 17957 MRW 33141 b

1    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
2    halide, 1-(N-methyl-2-piperidinyl)methyl, or
3    2-(4-morpholinyl)ethyl, whether or not further substituted
4    on the indazole ring to any extent: including, but not
5    limited to, APP-PICA and 5-fluoro-APP-PICA;
6        (76) 4-Acetoxy-N,N-dimethyltryptamine: trade name
7    4-AcO-DMT;
8        (77) 5-Methoxy-N-methyl-N-isopropyltryptamine: trade
9    name 5-MeO-MIPT;
10        (78) 4-hydroxy Diethyltryptamine (4-HO-DET);
11        (79) 4-hydroxy-N-methyl-N-ethyltryptamine (4-HO-MET);
12        (80) 4-hydroxy-N,N-diisopropyltryptamine (4-HO-DiPT);
13        (81) 4-hydroxy-N-methyl-N-isopropyltryptamine
14    (4-HO-MiPT);
15        (82) Fluorophenylpiperazine;
16        (83) Methoxetamine;
17        (84) 1-(Ethylamino)-2-phenylpropan-2-one (iso-
18    ethcathinone).
19    (e) Unless specifically excepted or unless listed in
20another schedule, any material, compound, mixture, or
21preparation which contains any quantity of the following
22substances having a depressant effect on the central nervous
23system, including its salts, isomers, and salts of isomers
24whenever the existence of such salts, isomers, and salts of
25isomers is possible within the specific chemical designation:
26        (1) mecloqualone;

 

 

SB2341 Enrolled- 44 -LRB100 17957 MRW 33141 b

1        (2) methaqualone; and
2        (3) gamma hydroxybutyric acid.
3    (f) Unless specifically excepted or unless listed in
4another schedule, any material, compound, mixture, or
5preparation which contains any quantity of the following
6substances having a stimulant effect on the central nervous
7system, including its salts, isomers, and salts of isomers:
8        (1) Fenethylline;
9        (2) N-ethylamphetamine;
10        (3) Aminorex (some other names:
11    2-amino-5-phenyl-2-oxazoline; aminoxaphen;
12    4-5-dihydro-5-phenyl-2-oxazolamine) and its
13    salts, optical isomers, and salts of optical isomers;
14        (4) Methcathinone (some other names:
15    2-methylamino-1-phenylpropan-1-one;
16    Ephedrone; 2-(methylamino)-propiophenone;
17    alpha-(methylamino)propiophenone; N-methylcathinone;
18    methycathinone; Monomethylpropion; UR 1431) and its
19    salts, optical isomers, and salts of optical isomers;
20        (5) Cathinone (some trade or other names:
21    2-aminopropiophenone; alpha-aminopropiophenone;
22    2-amino-1-phenyl-propanone; norephedrone);
23        (6) N,N-dimethylamphetamine (also known as:
24    N,N-alpha-trimethyl-benzeneethanamine;
25    N,N-alpha-trimethylphenethylamine);
26        (7) (+ or -) cis-4-methylaminorex  ((+ or -) cis-

 

 

SB2341 Enrolled- 45 -LRB100 17957 MRW 33141 b

1    4,5-dihydro-4-methyl-4-5-phenyl-2-oxazolamine);
2        (8) 3,4-Methylenedioxypyrovalerone (MDPV);
3        (9) Halogenated amphetamines and
4    methamphetamines - any compound derived from either
5    amphetamine or methamphetamine through the substitution
6    of a halogen on the phenyl ring, including, but not
7    limited to, 2-fluoroamphetamine, 3-
8    fluoroamphetamine and 4-fluoroamphetamine; 
9        (10) Aminopropylbenzofuran (APB):
10    including 4-(2-Aminopropyl) benzofuran, 5-
11    (2-Aminopropyl)benzofuran, 6-(2-Aminopropyl)
12    benzofuran, and 7-(2-Aminopropyl) benzofuran; 
13        (11) Aminopropyldihydrobenzofuran (APDB):
14    including 4-(2-Aminopropyl)-2,3- dihydrobenzofuran,
15    5-(2-Aminopropyl)-2, 3-dihydrobenzofuran,
16    6-(2-Aminopropyl)-2,3-dihydrobenzofuran,
17    and 7-(2-Aminopropyl)-2,3-dihydrobenzofuran; 
18        (12) Methylaminopropylbenzofuran
19    (MAPB): including 4-(2-methylaminopropyl)
20    benzofuran, 5-(2-methylaminopropyl)benzofuran,
21    6-(2-methylaminopropyl)benzofuran
22    and 7-(2-methylaminopropyl)benzofuran. 
23    (g) Temporary listing of substances subject to emergency
24scheduling. Any material, compound, mixture, or preparation
25that contains any quantity of the following substances:
26        (1) N-[1-benzyl-4-piperidyl]-N-phenylpropanamide

 

 

SB2341 Enrolled- 46 -LRB100 17957 MRW 33141 b

1    (benzylfentanyl), its optical isomers, isomers, salts, and
2    salts of isomers;
3        (2) N-[1(2-thienyl) methyl-4-piperidyl]-N-
4    phenylpropanamide (thenylfentanyl), its optical isomers,
5    salts, and salts of isomers.
6    (h) Synthetic cathinones. Unless specifically excepted,
7any chemical compound which is not approved by the United
8States Food and Drug Administration or, if approved, is not
9dispensed or possessed in accordance with State or federal law,
10not including bupropion, structurally derived from
112-aminopropan-1-one by substitution at the 1-position with
12either phenyl, naphthyl, or thiophene ring systems, whether or
13not the compound is further modified in one or more of the
14following ways:
15        (1) by substitution in the ring system to any extent
16    with alkyl, alkylenedioxy, alkoxy, haloalkyl, hydroxyl, or
17    halide substituents, whether or not further substituted in
18    the ring system by one or more other univalent
19    substituents. Examples of this class include, but are not
20    limited to, 3,4-Methylenedioxycathinone (bk-MDA);
21        (2) by substitution at the 3-position with an acyclic
22    alkyl substituent. Examples of this class include, but are
23    not limited to, 2-methylamino-1-phenylbutan-1-one
24    (buphedrone); or
25        (3) by substitution at the 2-amino nitrogen atom with
26    alkyl, dialkyl, benzyl, or methoxybenzyl groups, or by

 

 

SB2341 Enrolled- 47 -LRB100 17957 MRW 33141 b

1    inclusion of the 2-amino nitrogen atom in a cyclic
2    structure. Examples of this class include, but are not
3    limited to, Dimethylcathinone, Ethcathinone, and
4    a-Pyrrolidinopropiophenone (a-PPP); or .
5    Any other synthetic cathinone which is not approved by the
6United States Food and Drug Administration or, if approved, is
7not dispensed or possessed in accordance with State or federal
8law.
9    (i) Synthetic cannabinoids or piperazines. Any synthetic
10cannabinoid or piperazine which is not approved by the United
11States Food and Drug Administration or, if approved, which is
12not dispensed or possessed in accordance with State and federal
13law.
14(Source: P.A. 99-371, eff. 1-1-16; 100-201, eff. 8-18-17;
15100-368, eff. 1-1-18; revised 10-5-17.)